Rucaparib
BRCA1-Related Cancer Predisposition
Explore 10 assets in BRCA1-Related Cancer Predisposition →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Washington
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03442556CT.gov Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | — | Terminated | — | — | — |
NCT03552471CT.gov Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · BRCA1-Related Cancer Predisposition
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rucaparib (this asset) | University of Washington | P2 | B · 57 |
| Olaparib | M.D. Anderson Cancer Center | P2 | BB |
| Niraparib | Qian Qin | P3 | B |
| Veliparib | Steven J Isakoff, MD, PhD | P2 | B |
| Durvalumab | Roswell Park Cancer Institute | P2 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Roswell Park Cancer Institute | P2 | B |
| Pembrolizumab | Rutgers, The State University of New Jersey | P2 | CCC |
| Carboplatin | University of Washington | P2 | CCC |
| Dostarlimab | Dana-Farber Cancer Institute | P2 | CCC |
+8 more in the BRCA1-Related Cancer Predisposition cohort
Other indications for Rucaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peritoneum Cancer | — | P3 | BB · 66 |
| Ovarian Cancer | — | P3 | B · 61 |
| Ovarian Carcinoma | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- OlaparibM.D. Anderson Cancer CenterBB
- NiraparibQian QinB
- VeliparibSteven J Isakoff, MD, PhDB
- DurvalumabRoswell Park Cancer InstituteB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerRoswell Park Cancer InstituteB
Citation
Floatz Terminal. Rucaparib in BRCA1-Related Cancer Predisposition. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rucaparib-brca1-related-cancer-predisposition
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →